Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing prevalence of chronic respiratory conditions
3.2.1.2 Rising healthcare expenditure
3.2.1.3 Technological advancements in drug discovery
3.2.2 Industry pitfalls & challenges
3.2.2.1 Regulatory hurdles and approval challenges
3.2.2.2 Limited healthcare infrastructure in developing countries
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Pipeline analysis
3.6 Porter's analysis
3.7 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Drug Type, 2021 – 2032 ($ Mn)
5.1 Key trends
5.2 Palivizumab
5.3 Ribavirin
5.4 Motavizumab
5.5 Other drug types
Chapter 6 Market Estimates and Forecast, By Route of Administration, 2021 – 2032 ($ Mn)
6.1 Key trends
6.2 Oral
6.3 Injectable
6.4 Intranasal
6.5 Other route of administrations
Chapter 7 Market Estimates and Forecast, By Patient Type, 2021 – 2032 ($ Mn)
7.1 Key trends
7.2 Adult
7.3 Pediatrics
Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 – 2032 ($ Mn)
8.1 Key trends
8.2 Hospital pharmacies
8.3 Retail pharmacies & drug stores
8.4 Online pharmacies
Chapter 9 Market Estimates and Forecast, By Region, 2021 – 2032 ($ Mn)
9.1 Key trends
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 France
9.3.4 Spain
9.3.5 Italy
9.3.6 Netherlands
9.3.7 Rest of Europe
9.4 Asia Pacific
9.4.1 China
9.4.2 Japan
9.4.3 India
9.4.4 Australia
9.4.5 South Korea
9.4.6 Rest of Asia Pacific
9.5 Latin America
9.5.1 Brazil
9.5.2 Mexico
9.5.3 Argentina
9.5.4 Rest of Latin America
9.6 Middle East and Africa
9.6.1 South Africa
9.6.2 Saudi Arabia
9.6.3 UAE
9.6.4 Rest of Middle East and Africa
Chapter 10 Company Profiles
10.1 AbbVie Inc.
10.2 AstraZeneca PLC
10.3 Bausch Health Companies Inc.
10.4 Gilead Sciences
10.5 GSK plc
10.6 Johnson & Johnson
10.7 Medivir AB
10.8 Merck & Co., Inc
10.9 Pfizer Inc.
10.10 Sanofi